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Abstract
Both alterations of lipid/lipoprotein metabolism and inflammatory events con-
tribute to the formation of the atherosclerotic plaque, characterized by the
accumulation of abnormal amounts of cholesterol and macrophages in the artery
wall. Reverse cholesterol transport (RCT) may counteract the pathogenic events
leading to the formation and development of atheroma, by promoting the high-
density lipoprotein (HDL)-mediated removal of cholesterol from the artery wall.
Recent in vivo studies established the inverse relationship between RCT effi-
ciency and atherosclerotic cardiovascular diseases (CVD), thus suggesting that
the promotion of this process may represent a novel strategy to reduce athero-
sclerotic plaque burden and subsequent cardiovascular events. HDL plays a
primary role in all stages of RCT: (1) cholesterol efflux, where these lipoproteins
remove excess cholesterol from cells; (2) lipoprotein remodeling, where HDL
undergo structural modifications with possible impact on their function; and
(3) hepatic lipid uptake, where HDL releases cholesterol to the liver, for the final
excretion into bile and feces. Although the inverse association between HDL
plasma levels and CVD risk has been postulated for years, recently this concept
has been challenged by studies reporting that HDL antiatherogenic functions
may be independent of their plasma levels. Therefore, assessment of HDL
function, evaluated as the capacity to promote cell cholesterol efflux may offer
a better prediction of CVD than HDL levels alone. Consistent with this idea, it
has been recently demonstrated that the evaluation of serum cholesterol efflux
capacity (CEC) is a predictor of atherosclerosis extent in humans.
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LDL Low-density lipoproteins
LXR Liver X receptor
LXR/RXR Liver X receptor/retinoid X receptor
MPO Myeloperoxidase
NPC1L1 Niemann-Pick type C like 1
PLA2 Phospholipase A2
PLTP Phospholipid transfer protein
PPAR Peroxisome proliferator-activated receptor
RCT Reverse cholesterol transport
SR-BI Scavenger receptor class B type I
1 Cholesterol Efflux as the First Step of Reverse Cholesterol
Transport (RCT)
Lipid accumulation within macrophages, leading to the formation of foam cells,
represents a main feature of atherogenesis (Wynn et al. 2013). Among the strategies
by which cells may counteract this process, the release of excess cholesterol to
extracellular lipid acceptors has been matter of several studies in the recent years.
Although cholesterol efflux from macrophages has a minor contribution to the
whole body cholesterol transported by plasma high-density lipoproteins (HDL), it
is the most important for the antiatherosclerotic extent. For this reason, the macro-
phage RCT concept has been proposed, and it was recently identified as a novel
therapeutic target (Rosenson et al. 2012).
Both active and passive mechanisms are responsible for cholesterol efflux, and
several components, such as cell cholesterol status, lipid transporter activity, and
the nature of extracellular acceptors, have been shown to impact its efficiency
(Zanotti et al. 2012).
The efflux process involves cholesterol localized on the plasma membrane that
in turn may derive from intracellular sites, such as the late endosomal/lysosomal
compartment and from the Golgi apparatus. Cholesterol localized in the endoplas-
mic reticulum originates from endogenous synthesis and can be delivered to
intracellular organelles mainly through a nonvesicular pathway involving protein
carriers. Cholesterol in endosomes and lysosomes derives from lipoprotein uptake
and undergoes hydrolyzation by acid hydrolase (Maxfield and Tabas 2005). This
lipoprotein-derived cholesterol is then rapidly released into the cytoplasm and
delivered throughout the cells by Niemann-Pick type C 1 and 2. These proteins,
expressed on the membrane of late endosomes and in lysosomes, respectively,
facilitate lipid mobilization from these compartments to the plasma membranes
via the trans-Golgi network (Boadu and Francis 2006). In physiological conditions
cholesterol content in intracellular locations is low, because most of it (about 80 %)
is transferred to the plasma membrane, where it establishes a dynamic equilibrium
with endoplasmic reticulum and the Golgi system pools (Huang et al. 2003). The
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plasma membrane bilayer contains distinct lipid environments in a steady state
equilibrium. Lipid rafts are characterized by a tightly packed, liquid-ordered state,
where cholesterol associates with sphingolipids and caveolin, playing a crucial role
in cell signaling (Gargalovic and Dory 2003). Several studies carried out in
macrophages, demonstrated that the major mechanisms of cholesterol efflux are
raft-independent (Gargalovic and Dory 2003). The non-raft membrane
microdomains serve as the principal source of cholesterol available for interaction
with extracellular acceptors and subsequent efflux via ATP-binding cassette trans-
porter A1 (ABCA1) that is localized in these portions of the membrane (Landry
et al. 2006; Vaughan and Oram 2005). Interestingly, RCT can be triggered also
from extracellular matrix-associated cholesterol microdomains, whose formation is
mediated by ATP-binding cassette transporter G1 (ABCG1) (Freeman et al. 2013).
Mechanisms accounting for cholesterol efflux include passive diffusion pro-
cesses as well as active pathways mediated by ABCA1, ABCG1, and scavenger
receptor class B type I (SR-BI). Aqueous diffusion mainly involves free cholesterol
in the plasma membrane and HDL as lipid acceptors. The nature of this process is a
matter of debate: whereas this mechanism appears to be a relevant contributor of
lipid removal in foam cell macrophages (Adorni et al. 2007), the involvement of a
still unknown transporter is not completely ruled out.
1.1 ABCA1-Mediated Lipid Efflux to Lipid-Poor apoA-I
ABCA1 is a 2,261-amino acid integral membrane protein, member of the large
superfamily of ABC transporters that use ATP as an energy source to transport
lipids across membranes. ABC transporters are characterized by the presence of
nucleotide-binding domains containing two conserved peptide motifs known as
Walker A and Walker B, a unique amino acid signature between the two Walker
motifs, which defines the family. ABC transporters are integrated into the mem-
brane by domains containing six transmembrane helices. The minimum require-
ment for an active ABC transporter is two nucleotide-binding and two 6-helix
transmembrane domains (Oram and Lawn 2001). At the cellular level ABCA1 is
localized both on the plasma membrane and intracellular compartments, the Golgi
complex, and the late endosome/lysosomes, cycling between these loci and pro-
moting a flow of intracellular cholesterol from the late endosomes/lysosomes,
through the trans-Golgi complex, to the plasma membrane (Boadu and Francis
2006). This movement produces an ABCA1-dependent depletion of intracellular
pools of cholesterol that affects both the “regulatory” pool of cholesterol and the
LDL-derived cholesterol. These activities result in the modulation of a number of
cellular events including: endogenous cholesterol synthesis, LDL receptor expres-
sion, cholesteryl ester turnover, and nascent HDL formation (Boadu and Francis
2006). The last process is driven by ABCA1-mediated removal of lipids from the
cell membrane to extracellular acceptors represented by lipid-free or lipid-poor
apolipoproteins. ABCA1 expression on the plasma membrane leads to the genera-
tion of non-raft microdomains and enlargement of cholesterol and phospholipid
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domains in the outer leaflet, thus facilitating the interaction with apoA-I and
subsequent cholesterol efflux. It is worth noting that these pools of cholesterol
created by ABCA1 are specific substrates for ABCA1-mediated lipid release
because they selectively interact with lipid-free or lipid-poor apolipoproteins
(Landry et al. 2006). ABCA1 exerts its function through a floppase activity,
which drives cholesterol and phospholipids from the inner leaflet of the membrane
to cell surface domains and eventually back to intracellular compartments. In
addition, ABCA1 promotes vesicular trafficking of cholesterol, phospholipids and
ABCA1 itself between the plasma membrane and intracellular compartments
(Landry et al. 2006). Cholesterol efflux via ABCA1 is related to the protein level,
in turn regulated by transcriptional or posttranslational mechanisms. Abca1 gene
expression is primarily induced by the stimulation of liver X receptor/retinoid X
receptor (LXR/RXR) axis, stimulated by cholesterol accumulation in the cells
(Larrede et al. 2009). Recently, the role of microRNAs in the inhibitory control
of Abca1 expression has emerged (Sun et al. 2012; Rayner et al. 2010; Ramirez
et al. 2011). The posttranscriptional regulation includes mechanisms that involve
(1) the stabilization of ABCA1 protein by apoA-I and (2) the acceleration of its
turnover by calpain-mediated proteolysis or polyunsaturated fatty acids (Oram and
Vaughan 2006).
1.2 Cholesterol Efflux to Lipidated HDL
ABCA1-mediated generation of nascent HDL particles may in turn promote cho-
lesterol efflux via ABCG1 and SR-BI. The former is a half-size ABC protein, where
the nucleotide-binding domain at the N-terminus is followed by six
transmembrane-spanning domains. Interestingly, various transcripts of ABCG1
have been detected in different cells, possibly arising from alternative splicing
events (Schmitz et al. 2001). Early studies reported many similarities between
ABCG1 and ABCA1, including the cellular localization, the translocation from
intracellular compartments to the plasma membrane, the floppase activity, and the
expression promoted by cholesterol enrichment via LXR. A main feature of
ABCG1-mediated efflux is the specific interaction with HDL and low-density
lipoproteins (LDL) thus accounting for the elimination of cholesterol and toxic
oxysterols from the macrophages (Vaughan and Oram 2005). It is important to note
that under physiologic conditions ABCA1 and ABCG1 can act in a sequential
fashion, with ABCA1 generating, which then promote lipid release via ABCG1
(Gelissen et al. 2006). However, recent data challenge these concepts, suggesting
that, unlike ABCA1, ABCG1 effluxes cellular cholesterol by a process that is not
dependent upon interaction with an extracellular protein (Tarling and Edwards
2012).
Although several cholesterol-responsive ABC transporters, other than ABCA1
and ABCG1, have been described in the macrophages, their potential relevance for
the process of foam cell formation and RCT needs further investigations
(Fu et al. 2013).
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SR-BI is an 82-kDa integral membrane protein, belonging to the CD36 family,
whose physiological role is related to the selective uptake of HDL cholesteryl ester,
the process by which the core cholesteryl ester is taken into the cell without the
endocytic uptake and degradation of the whole HDL. Since this pathway is the
major route for the delivery of HDL cholesteryl ester to the liver, the role of SR-BI
in determining the plasma levels of HDL is of major importance. Importantly,
SR-BI has shown to stimulate free cholesterol efflux facilitating the aqueous
diffusion pathway to phospholipid-enriched acceptors. Thus, the expression of
this receptor establishes a bidirectional flux between cells and HDL, whose net
effect will be related to cell cholesterol status, as well as the composition and
concentration of the acceptor in the extracellular environment. Differently from the
ABC transporters, SR-BI is localized in caveolae, a subset of lipid rafts, cell surface
invaginations enriched in free cholesterol (Rosenson et al. 2012). Despite the
significant role of SR-BI in cell cholesterol metabolism, its role in cholesterol
efflux from macrophages is still unclear. It is important to note that the relative
contribution of a single pathway to cholesterol export is species specific: whereas
ABCA1-mediated efflux is the predominant mechanism both in human and murine
cultured foam cells, the role of ABCG1 is elusive in the former, but not in the latter.
Conversely, SR-BI (Cla-1 in humans) plays a pivotal role in human, but not murine
cells (Adorni et al. 2007; Sun et al. 2012). Moreover, the antiatherosclerotic
properties of ABCA1 and ABCG1 have recently been challenged by the demon-
stration that some efflux-independent activities could be related to deleterious
effects on macrophage function (Adorni et al. 2011; Olivier et al. 2012).
A relevant role in cholesterol efflux from macrophages and RCT has been also
attributed to apolipoprotein E (apoE) (Zanotti et al. 2011a, b). This 34-kDa protein
is synthesized by many cell types, including macrophages, upon different stimuli,
such as differentiation, cytokines, and lipid enrichment. The last process activates
the LXR pathway, as described for ABCA1 and ABCG1. ApoE synthesis in the
endoplasmic reticulum is followed by its movement to the Golgi and trans-Golgi
network and incorporation into vesicular structures, before being transported to the
plasma membrane for the final secretion. Secreted apoE can be released into the
extracellular medium or alternatively can bind to the cell surface, particularly in
association with heparan sulfate proteoglycans. Cell surface pools may be
reinternalized and subsequently degraded, transported to the Golgi network for
posttranslational modifications, or released into the extracellular medium (Kockx
et al. 2008). When ApoE is secreted from cholesterol-enriched macrophages, this
process can promote cholesterol efflux in the absence of added cholesterol
acceptors or in presence of exogenous HDL, causing the generation of nascent
HDL particles. There is evidence that apoE can promote cholesterol release by both
ABCA1-dependent and independent mechanisms, whereas ABCG1 may contribute
by driving cholesterol efflux to apoE-enriched particles (Huang et al. 2001).
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2 HDL Quality and Cholesterol Efflux
HDL comprises several subclasses that differ in composition and size and exhibit a
series of atheroprotective and other properties, including the ability to efflux
cholesterol from various cell types, as well as antioxidative, anti-inflammatory,
anticoagulatory, and anti-aggregatory properties (Annema and von Eckardstein
2013; Vickers and Remaley 2014). These properties are exerted by the various
protein and lipid components of HDL (Annema and von Eckardstein 2013; Vickers
and Remaley 2014). It is increasingly accepted that the quality rather than quantity
of HDL is more relevant for its atheroprotective activity (see chapter “Dysfunc
tional HDL: From Structure-Function-Relationships to Biomarkers” for more
details).
As anticipated, the ability of HDL to promote cholesterol efflux from lipid-laden
macrophages is thought to be important for the atheroprotective function of HDL.
The capacity of HDL to promote cholesterol efflux from macrophages was shown
to have a strong inverse association with both carotid intima–media thickness and
the likelihood of angiographic coronary artery disease, independently of the HDL-C
level (Khera et al. 2011). As mentioned before, cellular cholesterol efflux is
mediated by a number of pathways, with the various HDL subpopulations to display
a varied capacity to promote cholesterol efflux via each of these pathways (Annema
and von Eckardstein 2013; Vickers and Remaley 2014). Therefore, the efficiency of
serum from an individual to accept cellular cholesterol can be affected by the
distribution and composition of HDL particles acting as cholesterol acceptors.
Indeed, it has been shown that apolipoprotein B (apoB)-depleted sera from subjects
with similar HDL-C or apoA-I can have higher total macrophage efflux capacity
due to significantly higher ABCA1-mediated efflux, and this efflux is significantly
correlated with the levels of preβ1-HDL (de la Llera-Moya et al. 2010; Calabresi
et al. 2009). Small discoidal preβ1-HDL particles are also efficient acceptors of cell
cholesterol via ABCG1 (Favari et al. 2009). In another study, apoB-depleted sera
from patients treated with the cholesteryl ester transfer protein (CETP) inhibitor
anacetrapib were shown to have enhanced ability to promote ABCG1-mediated
cholesterol efflux from macrophages, which was associated with increased lecithin-
cholesterol acyltransferase (LCAT) and apoE mass in HDL (Yvan-Charvet
et al. 2010).
The various components of HDL particles can undergo structural or chemical
modifications during atherogenesis or other pathologic processes, having as a result
adverse effects on HDL functionality, including the cholesterol efflux capacity. In
vitro and in vivo studies have shown that enzymatic oxidation, lipolysis, and
proteolysis can modify HDL and affect the HDL capacity to promote cellular
cholesterol efflux. HDL isolated from humans with established CVD was found
to contain higher levels of protein-bound 3-chlorotyrosine and protein-bound
3-nitrotyrosine compared to HDL from controls (Bergt et al. 2004; Pennathur
et al. 2004; Zheng et al. 2004). In addition, the levels of both 3-chlorotyrosine
and 3-nitrotyrosine were higher in HDL isolated from atherosclerotic lesions
compared with plasma HDL. One pathway that generates such species involves
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myeloperoxidase (MPO), a major constituent of artery wall macrophages (Bergt
et al. 2004; Pennathur et al. 2004; Zheng et al. 2004). It was proposed that apoA-I is
a selective target for MPO-catalyzed nitration and chlorination in vivo and that
MPO-catalyzed oxidation of HDL and apoA-I results in selective inhibition of
ABCA1-dependent cholesterol efflux from macrophages (Zheng et al. 2004).
More specifically, it was shown that chlorination of apoA-I impaired the ability
of the protein to promote cholesterol efflux by MPO, while nitration had a much
lesser effect (Bergt et al. 2004; Zheng et al. 2005; Shao et al. 2005) and that a
combination of Tyr-192 chlorination and methionine oxidation is necessary for
depriving apoA-I of its ABCA1-dependent cholesterol transport activity (Shao
et al. 2006). More recently it was suggested that oxidative damage to apoA-I by
MPO limits the ability of apoA-I to be liberated in a lipid-free form from HDL and
that this impairment of apoA-I exchange reaction may contribute to reduced
ABCA1-mediated cholesterol efflux (Cavigiolio et al. 2010).
Treatment of HDL3 with the reticulocyte-type 15-lipoxygenase-1 (15-LO-1),
which has been suggested to play a pathophysiological role in atherosclerosis,
induced HDL apolipoprotein cross-linking and reduced cholesterol efflux from
lipid-laden J774 cells (Pirillo et al. 2006). A reduced binding of 15-LO-modified
HDL3 to SR-BI explained, in part, the observed reduction of cholesterol efflux. In
addition, the ABCA1-mediated cholesterol efflux was also reduced, as a conse-
quence of loss of preβ-particles after HDL3 modification (Pirillo et al. 2006).
The capacity of HDL to promote cellular cholesterol efflux from lipid-loaded
mouse peritoneal macrophages was significantly decreased after treatment of HDL
with secretory phospholipase A2 (PLA2) group X or V (Zanotti et al. 2011a, b).
sPLA2-X and sPLA2-V that have been associated with the pathogenesis of athero-
sclerosis affect the capacity of HDL to promote cholesterol efflux by catalyzing the
hydrolysis of phosphatidylcholine in HDL without any modification of apoA-I
(Ishimoto et al. 2003).
Several proteases, including metalloproteinases, cathepsins, chymase, tryptase,
kallikrein, neutrophil elastase, and plasmin, that are secreted from various types of
cells of human atherosclerotic arterial intima can proteolytically modify HDL
in vitro (Lee-Rueckert et al. 2011). It has been shown that the various proteases
proteolyze apoA-I that is present in preβ-HDL and therefore reduce cholesterol
efflux from macrophage foam cells (Favari et al. 2004). A series of studies aiming
to elucidate the effect of proteolytic modification of HDL on cholesterol efflux and
RCT used mast cells and the neutral serine proteases chymase and tryptase, which
are secreted from mast cells. Treatment of HDL3 with human chymase resulted in
rapid depletion of preβ-HDL and a concomitant decrease in the efflux of cholesterol
and phospholipids by an ABCA1-dependent pathway, while aqueous or SR-BI-
facilitated diffusion of cholesterol was not affected (Favari et al. 2004). Further-
more, local activation of mast cells by the specific mast cell degranulating com-
pound 48/80 in the mouse peritoneal cavity, which causes acute release of active
chymase, resulted in a 90 % reduction of human apoA-I injected into the peritoneal
cavity. This reduction reflected the reduction in preβ-HDL particles and resulted in
attenuation of cholesterol efflux from intraperitoneally co-injected J774
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macrophages and a reduced rate of macrophage RCT. In addition, pretreatment of
apoA-I with chymase also fully abolished the stimulatory effect of untreated apoA-I
to promote the transfer of macrophage-derived cholesterol to the intestine
(Lee-Rueckert, Silvennoinen et al. 2011).
Proteolysis of lipid-free apoA-I or preβ-HDL- or HDL3-associated apoA-I by
intima proteases may result in the formation of carboxy-terminal truncated apoA-I
fragments. Specifically, it has been shown recently that lipid-free apoA-I is prefer-
entially digested by chymase at the C-terminus rather than the N-terminus and that
the Phe229 and Tyr192 residues are the main cleavage sites, while the Phe225 residue
is a minor cleavage site (Usami et al. 2013). C-terminally truncated apoA-I was
detected in normal human serum using a specific monoclonal antibody (16-4mAb)
recognizing C-terminally truncated apoA-I that has been cleaved after Phe225 by
chymase (Usami et al. 2011). In addition, it has been shown that proteolysis of
apoA-I in preβ-HDL by plasmin generated apoA-I fragments lacking the
C-terminal region (Kunitake et al. 1990). Such C-terminal truncation of apoA-I
can affect its capacity to promote ABCA1-mediated cholesterol efflux and the
biogenesis of HDL. Previous studies showed that when C-terminal segments that
contain residues 220–231 are deleted, the apoA-I cannot associate with ABCA1 and
has a diminished capacity to promote ABCA1-mediated phospholipid cholesterol
efflux (Favari et al. 2002; Chroni et al. 2003, 2004). In another study, the treatment
of lipid-free human apoA-I by chymase-containing lysate derived from mouse
peritoneal mast cells or recombinant human chymase generated apoA-I fragments,
lacking the C-terminal site (Usami et al. 2013), which had diminished capacity to
promote cholesterol efflux from mouse peritoneal macrophage foam cells
(Lee-Rueckert, Silvennoinen et al. 2011). Furthermore, adenovirus-mediated gene
transfer in apoA-I-deficient mice showed that the apoA-I mutants that lack
C-terminal residues 220–231 fail to form spherical αHDL in vivo (Chroni
et al. 2003, 2007).
Other proteolysis studies showed that apoA-I in HDL3 by various recombinant
metalloproteinases in vitro or by metalloproteinases secreted from macrophages
generated apoA-I fragments also lacking the carboxyl-terminal region (cleavage
after residues 213, 202, 215, 225,199, 191, or 188) (Lindstedt et al. 1999; Eberini
et al. 2002). In addition, chymase, in vitro, cleaves apoA-I in reconstituted HDL at
the C-terminus (after Phe225) (Lee et al. 2003). These C-terminal truncated
lipoprotein-associated apoA-I displayed diminished capacity to promote choles-
terol efflux from mouse macrophage foam cells (Lindstedt et al. 1999; Lee
et al. 2003). A recent study showed that reconstituted HDL containing the
C-terminal deletion mutants apoA-I(Δ(185–243)) or apoA-I(Δ(220–243)) had
strongly impaired capacity to promote ABCG1-mediated cholesterol efflux (Daniil
et al. 2013). In addition, limited proteolysis of rHDL containing wild-type apoA-I
by plasmin resulted in 66 % decrease of ABCG1-dependent cholesterol efflux
(Daniil et al. 2013). It is therefore possible that proteolysis of HDL-associated
apoA-I in vivo by proteases, which are present in the human arterial intima, could
yield apoA-I fragments similar to the apoA-I(Δ(185–243)) or apoA-I(Δ(220–243))
mutants and thus may impair their capacity to promote ABCG1-mediated
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cholesterol efflux from macrophages. The structure-function relationship seen in
this study between rHDL-associated apoA-I mutants and ABCG1-mediated cho-
lesterol efflux closely resembles that seen before in lipid-free apoA-I mutants and
ABCA1-dependent cholesterol efflux, suggesting that both processes depend on the
same structural determinants of apoA-I.
The levels, composition, and the antiatherogenic properties, including the
cholesterol efflux capacity, of HDL has been shown to be affected in patients
suffering from chronic inflammatory rheumatic diseases (Onat and Direskeneli
2012; Watanabe et al. 2012). Specifically, cholesterol efflux capacity of HDL was
impaired in rheumatoid arthritis and systemic lupus erythematosus patients with
high disease activity and was correlated with systemic inflammation, higher plasma
MPO activity, and HDL’s antioxidant capacity (Ronda et al. 2013; Charles-
Schoeman et al. 2012). In addition, HDL cholesterol efflux capacity was lower in
patients with psoriasis (Watanabe et al. 2012; Holzer et al. 2013), while
antipsoriatic therapy significantly improved the HDL cholesterol efflux capacity,
along with improved serum LCAT activity and without any effect on serum HDL
cholesterol levels (Holzer et al. 2013).
Overall, modifications of HDL particles have been demonstrated to affect the
atheroprotective properties of HDL, including its capacity to promote cellular
cholesterol efflux. Elucidation of the conditions and processes that affect the
compositional, structural, and functional intactness of HDL may become an impor-
tant tool for the assessment of cardiovascular risk and may provide us with novel
therapeutic approaches. In addition, monitoring of the capacity of HDL to promote
cholesterol efflux could be useful to evaluate novel therapeutic approaches for the
reduction of cardiovascular risk, as it will be discussed later.
3 RCT in Animal Models
3.1 Physiology
The term RCT summarizes the transport of cholesterol from macrophage foam cells
within atherosclerotic lesions through the aqueous compartment of the blood for
final excretion into the feces, which could either occur directly as cholesterol or
after metabolic conversion into bile acids (Annema and Tietge 2012). As detailed
above, cholesterol efflux from lipid-laden macrophages is mediated by the
transporters ABCA1, ABCG1, and SR-BI with HDL as acceptor, and this process
is facilitated by apoE. Within the blood HDL can be remodeled in several ways.
LCAT esterifies free cholesterol in the particles resulting in larger HDL and
increased plasma HDL-C levels (Annema and Tietge 2012). CETP transfers cho-
lesterol out of HDL toward apoB-containing lipoproteins in exchange for
triglycerides, which are then rapidly hydrolyzed by hepatic lipase (HL) (Annema
and Tietge 2012). Thereby CETP and also HL, either alone or in combination,
lower plasma HDL-C levels. Other HDL remodeling proteins that increase the
catabolic rate of HDL and lower circulating HDL-C are the phospholipid transfer
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protein (PLTP) (Annema and Tietge 2012) and the phospholipases endothelial
lipase (EL) (Annema and Tietge 2011) and group IIA secretory phospholipase A2
(sPLA2-IIA) (Rosenson and Hurt-Camejo 2012) . Uptake of HDL-C into
hepatocytes can be accomplished in two distinct ways, via selective uptake
mediated by SR-BI (Annema and Tietge 2012) or via holoparticle uptake in a
process that has not been fully elucidated yet (Vantourout et al. 2010). However, it
has been shown that via ectopic localization of the mitochondrial F1-beta-ATPase
on the cell membrane, ADP is generated which then stimulates via the ADP
receptor P2Y13 holoparticle uptake of HDL by still elusive receptor mechanisms;
thereby, HDL holoparticle uptake is fully dependent on the expression of the ADP
receptor P2Y13 (Vantourout et al. 2010). In hepatocytes, cholesterol is either
secreted directly into the bile, which is mediated in terms of mass mainly by
ABCG5/G8 and to a lesser extent by SR-BI, or following conversion into bile
acids, for which ABCB11 is the critical transporter into bile (Dikkers and Tietge
2010). Cholesterol can be reabsorbed in the intestine by Niemann-Pick type C like
1 (NPC1L1) but also (re)secreted by the ABCG5/G8 heterodimer, whereby a low
activity of NPC1L1 would increase and a low activity of ABCG5/G8 would
decrease cholesterol excretion into the feces (Annema and Tietge 2012). Bile
acids can be reabsorbed in the terminal ileum by ASBT (Dawson 2011). In addition
to its role in sterol absorption, the intestine has also been indicated to mediate direct
secretion of cholesterol, a process termed transintestinal cholesterol excretion
[TICE, current knowledge summarized in Tietge and Groen (2013)]. All different
steps discussed in this paragraph have the potential to impact on and modulate RCT.
3.1.1 Methodological Approaches to Quantify RCT In Vivo
The key methodological problem for quantifying RCT specifically from
macrophages, which is most relevant for atherosclerotic disease, is that the macro-
phage cholesterol pool is rather small. Initially employed techniques such as mass
determinations of centripetal cholesterol fluxes to the liver or isotope dilution
methods were therefore not able to accurately allow a conclusion of specific
cholesterol fluxes from macrophages (Annema and Tietge 2012). Recently, a now
widely used and accepted technique had been developed that overcomes such
methodological drawbacks (Zhang et al. 2003). Thereby, macrophages, either
primary or cell lines, are loaded with radiolabeled cholesterol and then injected
intraperitoneally into recipient animals. After injection, the appearance of the tracer
is determined in plasma at different time points and, most importantly, in the feces
that are collected continuously. The time course of such experiments is usually
24–48 h; in the feces distinguishing between labels in neutral sterols and bile acids
is in our view preferable.
Although this method allows tracing of cholesterol from macrophages to feces,
there are certain limitations that need to be taken into account when interpreting
results from such studies. One is that in the assay a potential influx of cholesterol
from the plasma compartment into the macrophage is not taken into account. As
first steps to overcome this, two approaches were reported, in which the application
procedure of the labeled macrophages is modified in a way that allows reisolation of
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the cells to measure label as well as mass cholesterol content. One of these
approaches makes use of Matrigel plugs that are implanted subcutaneously
(Malik and Smith 2009), while the other another, entrapment of the macrophages
in semipermeable holofibers (Weibel et al. 2011). Another limitation of in vivo
RCT assays is that all approaches place the labeled macrophages outside the
vascular compartment, which supposedly is a good surrogate but might also not
accurately reflect the situation in an atherosclerotic lesion in terms of oxygen
tension, pH, or accessibility by the HDL particles. In the following, results obtained
from the above-described method will be summarized. It is relevant to point out that
although initial steps toward a macrophage RCT assay in humans have been
reported at conferences (Dunbar et al. 2013), current knowledge on the regulation
of in vivo RCT is based on studies in animal models that differ in several aspects of
their lipoprotein metabolism.
3.1.2 Factors Impacting In Vivo RCT
Looking at the level of the macrophage, available studies consistently indicate that
expression of ABCA1 and ABCG1 is associated with increased RCT (Wang
et al. 2007a, b; Out et al. 2008). However, SR-BI deficiency in macrophages does
not impact RCT (Wang et al. 2007b; Zhao et al. 2011). On the other hand,
macrophage apoE was shown to stimulate RCT (Zanotti et al. 2011a, b).
Regarding plasma proteins that have a role in HDL metabolism, for LCAT
surprisingly no consistent effects on RCT were observed using several different
models and overexpression as well as knockout strategies resulting in the conclu-
sion that LCAT only minimally contributes to RCT although it has a major role in
determining plasma HDL-C levels (Tanigawa et al. 2009). In the case of the lipid
transfer proteins, PLTP overexpression resulted in increased RCT (Samyn
et al. 2009), while for CETP (over)expressing models, either an increase (Tchoua
et al. 2008; Tanigawa et al. 2007), dependent on functional expression of the LDL
receptor (Tanigawa et al. 2007), or no effect (Rotllan et al. 2008) was observed.
With respect to (phospho)lipases, sPLA2-IIA had no impact on RCT (Annema
et al. 2010). In case of HL and EL, conflicting data have been reported. While
one group found no effect of knocking out either lipase separate or both in
combination (Brown et al. 2010), others reported increased RCT for EL as well
as HL (Escola-Gil et al. 2013). In contrast to apoE expression in macrophages,
systemic overexpression of apoE had no effect on RCT either in wild-type or CETP
transgenic mice (Annema et al. 2012).
In the case of the hepatic component of RCT, SR-BI expression in hepatocytes
has a clear increasing effect on RCT as indicated in studies using both knockout and
overexpression (Zhao et al. 2011; El Bouhassani et al. 2011; Zhang et al. 2005).
Interestingly, it has been shown that in the liver the impact of SR-BI is independent
of ABCG5/G8 expression, since double-knockout mice for both transporters had a
significant decrease in RCT compared with ABCG5 knockout mice alone (Dikkers
et al. 2013). ABCG5/G8 knockouts on the other hand exhibited no change in RCT
(Calpe-Berdiel et al. 2008). In addition, also the consequences of abolishing
functional HDL holoparticle uptake into hepatocytes on RCT were assessed. In
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P2Y13 knockout mice, this pathway is completely absent translating into a signifi-
cant reduction in macrophage-to-feces RCT (Fabre et al. 2010; Lichtenstein
et al. 2013). These combined studies indicate that both selective uptake and
holoparticle uptake of HDL are critical for RCT. Regarding expression of
ABCA1 in hepatocytes, liver supposedly contributes around 70 % to total HDL
formation (Timmins et al. 2005); the picture is not so clear. While in wild-type and
SR-BI knockout mice blocking hepatic ABCA1 with probucol enhanced RCT
(Annema et al. 2012; Yamamoto et al. 2011), no such effect was seen in liver-
specific ABCA1 knockout mice on a LDLR-deficient background (Bi et al. 2013).
With respect to the final step of RCT, sterol excretion from the body, the
differential contribution of the biliary pathway and the intestine is a subject of
active study; it might be important to note that no unequivocally established
concept has emerged thus far. The classical view on the RCT pathway puts biliary
secretion of RCT-relevant cholesterol central (Annema and Tietge 2012). This view
is supported by studies using either surgical disruption of biliary secretion or Abcb4
knockout mice that have a genetic defect in cholesterol secretion into the bile
secondary to their inability to secrete phospholipids and form mixed micelles
(Nijstad et al. 2011). In the surgical model RCT was virtually absent, while in the
genetic model, RCT was strongly reduced (Nijstad et al. 2011). Studies in
ezetimibe-treated mice that express NPC1L1 only in hepatocytes reached a similar
conclusion, namely, that functional RCT in this model depended on efficient biliary
sterol secretion (Xie et al. 2013). On the other hand, RCT studies in NPC1L1 liver-
transgenic mice on a wild-type background as well as a short-term experiment in
bile-diverted mice resulted in opposite findings, namely, that RCT can proceed
when the biliary secretion pathway is impaired (Temel et al. 2010). Further studies
are clearly required to assess the role of the intestine and a possible contribution of
TICE to macrophage RCT. However, currently such experiments are hampered by
the lack of information how TICE is precisely mediated (Tietge and Groen 2013).
Commonly accepted on the other hand is the role of intestinal sterol absorption in
RCT, and several pharmacological intervention studies were carried out to show
that blocking sterol absorption increases RCT (for details please see Table 1 and
text above).
In addition, there are also more complex systemic pathophysiological states that
are clinically associated with an increased atherosclerosis incidence and in which
also alterations in RCT have been observed in mouse models. One example is an
inflammatory response. Consistently, RCT was severely impaired in LPS- (Annema
et al. 2010; McGillicuddy et al. 2009) and zymosan-induced (Malik et al. 2011)
models of acute inflammation. Another example is diabetes. In both, an insulin-
deficient model of type 1 diabetes (de Boer et al. 2012) as well as in db/db mice
(Low et al. 2012), which lack the leptin receptor and serve as model of type
2 diabetes, RCT was decreased. Interestingly, the first study indicated that the
selective uptake step of HDL into the liver is defective in type 1 diabetic mice
(de Boer et al. 2012), while the latter study provided evidence that advanced
glycation end products are not likely to be pathophysiologically involved (Low
et al. 2012). Furthermore, acute psychological stress has been shown to increase
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RCT in mice, mainly by a corticosterone-mediated downregulation of NPC1L1 and
subsequent reduction in intestinal cholesterol absorption (Silvennoinen et al. 2012).
These data underline the important role of intestinal NPC1L1 in RCT but are
counterintuitive to the increased atherosclerosis risk attributed to psychological
stress in clinical settings.
Finally, two recent additions of pathways that are linked to RCT have emerged
which are not so obvious given the classical view on the RCT pathway but are
worth mentioning. On the one hand, red blood cells were shown to contribute to
RCT in a way that functional RCT was decreased in anemic mice (Hung
et al. 2012). On the other hand, lymphatic drainage has been indicated to be
involved in RCT (Martel et al. 2013; Lim et al. 2013). Hereby, blocking lymphatic
transport or lymph vessel regrowth inhibited RCT, while enabling it increased RCT
(Martel et al. 2013; Lim et al. 2013). Interestingly, for this route of RCT,
transcytosis of HDL through lymphatic endothelium in a SR-BI-dependent fashion
was critical (Lim et al. 2013), findings very similar to the role of SR-BI in HDL
transcytosis through vascular endothelial cells (Rohrer et al. 2009).
3.2 Pharmacology
RCT-enhancing therapies are currently considered a promising strategy for the
prevention and treatment of atherosclerotic CVD. An important number of
RCT-targeted drugs have been used in preclinical animal models (mainly mice
and hamsters) to test their effects on in vivo RCT from labeled cholesterol
macrophages to feces. These RCT-targeted drugs can be classified among four
different therapeutic approaches: CETP inhibition, nuclear receptors activation,
cholesterol absorption inhibition, and directly augmenting or mimicking apoA-I.
Most of these drugs are being used in clinical practice or tested in clinical trials in
phases I, II, or III. This section discusses recent findings indicating that some of
these therapies may be atheroprotective by promoting RCT in vivo (Table 1 shows
a summary of available data).
3.2.1 CETP Inhibitors
CETP inhibition presents a preferential target for raising HDL-C and enhancing
RCT. However, available data on the effect of the CETP inhibitors torcetrapib,
dalcetrapib, and anacetrapib in macrophage-to-feces RCT have produced divergent
results (Tchoua et al. 2008; Briand et al. 2011; Niesor et al. 2010; Castro-Perez
et al. 2011). These controversial effects, together with the disappointing results of
two large clinical trials using torcetrapib and dalcetrapib, have raised reasonable
doubts regarding the clinical use of CETP inhibitors (Barter and Rye 2012). The
positive effects of CETP antisense oligonucleotides on macrophage RCT (Bell
et al. 2013) open up an alternative pathway to further evaluate whether the inhibi-
tion of CETP may improve cardiovascular risk.
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3.2.2 Nuclear Receptor Activation
Liver X receptor (LXR) is considered an attractive target for therapeutic strategies
aimed at stimulating RCT since it promotes HDL biogenesis, macrophage choles-
terol efflux, and biliary cholesterol excretion. A considerable number of studies
tested the effect of systemic LXR agonists T0901317 and GW3965 on macrophage-
to-feces RCT and consistently found a higher flux through this pathway (Naik
et al. 2006; Zanotti et al. 2008; Calpe-Berdiel et al. 2008; Yasuda et al. 2010;
Nijstad et al. 2011; Briand et al. 2010). However, systemic LXR activators have
detrimental consequences for the liver such as the induction of lipogenesis. As
discussed in Sect. 3.1.2, multiple evidences indicate that excretion of macrophage-
derived cholesterol can be modulated in the last step of RCT pathway which occurs
in the small intestine. Indeed, intestine-specific LXR activator GW6340 also
enhances macrophage RCT but avoids the lipogenic toxicity associated with liver
LXR activation in mice (Yasuda et al. 2010). Peroxisome proliferator-activated
receptor (PPAR) α agonists such as GW7647 and fenofibrate promote macrophage
RCT (Rotllan et al. 2011; Nakaya et al. 2011). This effect is strongly correlated with
the positive effects on apoA-I levels; more importantly, macrophage PPARα and
LXR expression are required for the PPARα-mediated enhancement of macrophage
RCT (Nakaya et al. 2011). ABCA1 and G1 are targeted for degradation by
microRNA (miR)-33, an intronic microRNA located within the SREBF2 gene;
anti–miR-33 therapy enhances macrophage RCT (Rayner et al. 2011). In contrast,
the PPARγ agonist GW7845 reduces macrophage RCT. The authors hypothesize
that GW7845 redirects macrophage-derived cholesterol to adipose tissue via
SR-BI, thereby reducing its biliary excretion (Toh et al. 2011). Beyond PPAR-
LXR activation, the farnesoid X receptor (FXR) agonist GW4064 also promotes
macrophage-to-feces RCT; this effect is related to liver SR-BI upregulation and
reduced intestinal cholesterol absorption (Zhang et al. 2010).
3.2.3 Cholesterol Absorption Inhibitors
Interventions that inhibit cholesterol absorption including ezetimibe administration
and PPAR β/δ activation with GW0742 increase the excretion of macrophage-
derived cholesterol in feces by reducing intestinal NPC1L1 activity (Briand
et al. 2009; Sehayek and Hazen 2008; Silvennoinen et al. 2012; Maugeais
et al. 2013). The bile acid sequestrant cholestyramine also promotes macrophage-
to-feces RCT (Maugeais et al. 2013).
3.2.4 Augmenting or Mimicking apoA-I
The use of apoA-I and its different forms for the prevention and treatment of
atherosclerosis is a long-term goal of many laboratories. The full-length apoA-I,
reconstituted apoA-I-containing HDL, or apoA-I mimetics D4-F, ATI-5261, and
5A have been demonstrated to be effective for enhancing macrophage-to-feces
RCT in different mouse models (Maugeais et al. 2013; Lee-Rueckert and Kovanen
2011; Navab et al. 2004; Bielicki et al. 2010; Amar et al. 2010). The upregulation of
liver apoA-I production, as occurred with the thienotriazolodiazepine Ro 11-1464,
also enhances macrophage RCT (Zanotti et al. 2011a, b).
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4 Serum Cholesterol Efflux Capacity (CEC)
Several epidemiological studies define HDL as the most powerful plasmatic factor
with atheroprotective activity in humans (Di Angelantonio et al. 2009); a 1 mg/dl
increase of plasma HDL-C is associated with a 3–4 % reduction in cardiovascular
mortality (Assmann et al. 2002). Some post hoc analyses from randomized con-
trolled trials also suggest that raising HDL-C beneficially affects the risk of CVD
(Toth et al. 2013). However, the clinical efficacy of raising plasma HDL-C levels to
achieve cardiovascular risk reduction has been difficult to prove. Recently
published outcome trials involving the addition of niacin or dalcetrapib to standard
low-density lipoprotein cholesterol reduction therapy failed to demonstrate clinical
benefit despite increases in HDL-C ((AIM-HIGH) trial 2011; Schwartz et al. 2012).
Furthermore, genetic variants associated with increased HDL-C, thus conferring
lifelong exposure to higher circulating levels, are not consistently associated with
improved vascular outcomes (Voight et al. 2012). These findings have reinforced
the idea that changes in HDL-C levels are an inadequate surrogate for therapeutic
use. Therefore, an emerging concept is that of the quality of HDL, which are
heterogeneous in terms of size, charge, and lipid content (Calabresi et al. 2010)
and display functional differences, such as cell cholesterol efflux promotion.
Animal studies have suggested that HDL-mediated cholesterol flux through the
different RCT steps is a better predictor of the atherosclerotic impact of various
genetic and pharmacological perturbations than static, mass-based quantification of
circulating HDL-C (Rader et al. 2009). The efficacy of such HDL function in a
single individual may be estimated by measuring the cholesterol efflux capacity
(CEC) using widely standardized techniques that allow distinguishing between the
various mechanisms involved (Adorni et al. 2007). Several lines of evidence
suggest that CEC is sensitive to HDL composition rather than HDL-C plasma
levels; for instance, it has been shown that the serum capacity to promote choles-
terol efflux via ABCA1 strictly depends on the nascent (preβ) HDL plasma levels
(de la Llera-Moya et al. 2010; Favari et al. 2004). Subjects with the apoA-IMilano
mutation or LCAT deficiency have high levels of circulating particles and efficient
serum ability to induce macrophage cholesterol depletion despite very low HDL
levels (Favari et al. 2007; Calabresi et al. 2009). Thus, there is increasing evidence
that the measure of HDL functionality in different populations may be a better
predictor of coronary artery disease than the measure of absolute HDL-C levels
(Khera et al. 2011). As mentioned before, this concept is consistent with studies
revealing that subjects affected by CVD not only have HDL deficiency but also
major rearrangements of their composition (Campos et al. 1995; Sweetnam
et al. 1994) and consequently function. The role of serum CEC as an index of
cardiovascular protection has been suggested by a recent study demonstrating that
in two distinct cohorts of subjects, the CEC variable has a stronger predictive power
of the carotid intima-media thickness, an index of subclinical atherosclerosis, than
plasma HDL-C levels (Khera et al. 2011). In addition, in a population of healthy
subjects, ABCA1-mediated serum CEC was inversely correlated with pulse wave
velocity, an index of arterial stiffness, independent of HDL-C serum levels (Favari
198 E. Favari et al.
et al. 2013). A work measuring the flow-mediated dilation, as a parameter of
endothelial function, showed a positive correlation with the ABCA1-mediated
efflux pathway confirming the concept that the functional measures of HDL
might be a better marker for cardiovascular risk rather than HDL cholesterol levels
(Vazquez et al. 2012). Recently, Li and colleagues provided data indicating that
individuals in the top tertile of CEC had a moderately increased risk of a composite
cardiovascular end point of incident myocardial infarction, stroke, or death during
3 years of follow-up (Li et al. 2013). However, in the same study, CEC was
inversely associated with coronary artery disease. The reasons for this apparently
contradictory findings require further evaluation, but may be related to the
characteristics of the population involved in the study (Khera and Rader 2013).
Overall, the available data suggest that evaluation of CEC may better correlate with
coronary artery diseases than HDL-C; however, further studies are required to
demonstrate its role as predictor of cardiovascular event risk.
Conclusions
RCT provides a physiological strategy of protection from atherosclerosis. HDL
plays a leading role by promoting the removal of excess cholesterol in the arterial
wall through the induction of cellular cholesterol efflux from cells. Cholesterol
efflux represents the first and perhaps most important step of RCT. The ability of
HDL to promote cholesterol efflux depends on their quality and the pathologic
processes that induce their modifications. Many of the available data on the
physiology and pharmacology of RCT depend on studies in animal models that
have demonstrated that the enhancement of RCT is inversely correlated with the
development of atherosclerosis. In humans, the efficiency of the RCT can be
evaluated with the surrogate parameter of serum cholesterol efflux capacity
(CEC) that indicates the ability of HDL to promote efflux of cholesterol in the
individual patient. Recent clinical data suggest that the evaluation of CEC is a
strong predictor of atherosclerosis extent in humans and may represent in the
future a useful biomarker of cardiovascular risk.
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